Cardiogenic shock (CS) remains a highly morbid and lethal complication, with short-term mortality rates ranging from 35-50%. Despite advances in revascularization and temporary mechanical circulatory support (tMCS), randomized clinical trials (RCTs) have fallen short in identifying treatment strategies that improve survival.

The Evaluation and Management of Cardiogenic Shock virtual Heart House Roundtable aims to delve into various aspects of CS, including early identification and initial management, optimal hemodynamic monitoring, pharmacological therapies, mechanical circulatory support, and critical care management and weaning.